Article
Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Nature - 30 Apr 2015
Kreiter Sebastian, Vormehr Mathias, van de Roemer Niels, Diken Mustafa, Löwer Martin, Diekmann Jan, Boegel Sebastian, Schrörs Barbara, Vascotto Fulvia, Castle John C, Tadmor Arbel D, Schoenberger Stephen P, Huber Christoph, Türeci Özlem, Sahin Ugur
Abstract excerpt
Tumour-specific mutations are ideal targets for cancer immunotherapy as they lack expression in healthy tissues and can potentially be recognized as neo-antigens by the mature T-cell repertoire. Their systematic targeting by vaccine approaches, however, has been hampered by the fact that every patient's tumour possesses a unique set of mutations ('the mutanome') that must first be identified. Recently, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.